Journal News

Study reveals experimental targets for lymphoma research

Caleigh Findley
June 3, 2021

Lymphocytes, white blood cells made in the bone marrow, are an essential part of the immune system. The two main types of lymphocytes, T cells and B cells, carry out an adaptive immune response. B cells target circulating pathogens in the body, and T cells manage cell response to infection.

Lymphoma-445x334.jpg
National Institute of Allergy and Infectious Diseases,
National Institutes of Health
T lymphocytes like the one pictured manage cell response to infection, and mutations
that arise during their production in the bone marrow can lead to lymphomas.

During the production of these immune cells, called hematopoiesis, mutations can lead to T-cell or B-cell lymphomas. During hematopoiesis, genes sometimes are said to be turned "on" or "off" through a biological process called DNA methylation. This occurs when a methyl group is added to the DNA power switch that controls the expression of that gene. A family of enzymes called DNA methyltransferases, or Dnmts, carries out this process and is an important part of cellular function.

A new study in the Journal of Biological Chemistry reports that one DNA methylation enzyme, Dnmt3b, suppresses the development of lymphomas through its catalytic and noncatalytic functions. The authors, researchers at the universities of Florida and Nebraska, also provide evidence for a molecular pathway possibly involved in lymphoma development related to mutated Dnmt3b.

Previous research linked mutations to Dnmt3b with lymphoma development — alongside other diseases that impair the immune system. Dnmt3b influences the expression or silencing of genes, an important aspect for cancer research, as Dnmt3b suppresses tumor development. Decreased activity of Dnmt3b is linked to a rare disease called immunodeficiency-centromeric instability-facial anomalies syndrome and also human chronic lymphocytic leukemia, leading researchers to wonder if loss of Dnmt3b catalytic activity is a major factor in blood cancer.

Katarina Lopusna and colleagues investigated the significance of Dnmt3b in lymphoma using several experimental mouse models. The researchers generated mice lacking Dnmt3b's catalytic activity for one or both of the genetic alleles and compared them to mice with only one Dnmt3b allele. Knocking out one allele of Dnmt3b decreases all of its functions, including accessory jobs such as recruiting other Dnmts or influencing gene expression (outside of methylation). Taking away the catalytic activity of Dnmt3b, even partially, should hinder DNA methylation specifically, reducing production of blood cells and possibly tumorigenesis.

This study design yielded unexpected results for lymphoma development, according to Eric Fearon, an associate editor for the Journal of Biological Chemistry. "(In) an interesting twist … mice heterozygous for a null (complete loss-of-function) Dnmt3b allele developed T-cell malignancies," Fearon wrote in an email. "In contrast, mice that expressed a Dnmt3b allele encoding a DNMT3b protein that lacked catalytic activity developed B-cell malignancies."

These findings demonstrate that both the catalytic activity and accessory functions of Dnmt3b are important for fighting cancer.

The researchers investigated molecular mechanisms that could explain the link between Dnmt3b and blood cancer. Genomewide analysis revealed decreased methylation and increased expression of tumor-promoting genes. The results also showed reduced expression of the p53 pathway, known for preventing T-cell transformation.

The researchers' efforts "highlight how careful analysis of mutant alleles in mouse models can yield insights into the potential non-catalytic functions of certain enzymes, such as Dnmt3b," Fearon wrote. The study also puts forth potential molecular targets that may contribute to Dnmt3b-related tumor development for future research.

Caleigh Findley

Caleigh Findley is a fourth-year Ph.D. candidate in pharmacology and neuroscience at Southern Illinois University School of Medicine.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

A balancing game with implications for neurodegenerative disease
Journal News

A balancing game with implications for neurodegenerative disease

June 8, 2021

The relationship between two proteins, one essential to mitochondrial fission and the other found in Alzheimer’s tissue, might hold the key to how disease alters the fission–fusion balance.

Can people vaccinated against COVID-19 still spread the coronavirus?
News

Can people vaccinated against COVID-19 still spread the coronavirus?

June 6, 2021

Preliminary evidence seems to suggest that someone who’s vaccinated is less likely transmit the virus, but the proof is not yet ironclad.

Addgene expands its collection into antibodies
News

Addgene expands its collection into antibodies

June 4, 2021

The reagent repository Addgene, known for distribution and quality control of plasmids for open science, is expanding into recombinant antibodies and nanobodies in partnership with NeuroMab.

Exploring underappreciated molecules and new cities
Interview

Exploring underappreciated molecules and new cities

June 2, 2021

Neurochemist Xianlin Han has been an associate editor for the Journal of Lipid Research since 2019.

Researchers target cell membrane for cancer research
Journal News

Researchers target cell membrane for cancer research

June 1, 2021

“The central idea is that if you alter the composition of the cell membrane, you can potentially alter the functionality of the proteins within the membrane and thus the disease overall.”

Could the immune system be key to Alzheimer’s disease?
News

Could the immune system be key to Alzheimer’s disease?

May 30, 2021

Increasing evidence suggests that chronic inflammation takes a toll on the brain over the course of a lifetime